Thousands of men battling prostate cancer are set to gain access to a life-extending drug on the NHS following a significant ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...

Radiopharmaceutical therapy (RPT) combined with external beam radiotherapy (EBRT) is emerging as a powerful approach in prostate cancer treatment. Historically rooted in early 89Sr trials, this ...

Cribriform-negative disease had a low metastasis rate unaffected by treatment. After radiation therapy with neoadjuvant ADT group, men with cribriform-positive disease had the same metastasis rate as ...

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

The NHS has announced that the drug, abiraterone, will be offered to men with high-risk prostate cancer that has not yet ...

Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.

After 6 months of hormone therapy, men with prostate cancer showed worsening lipid profiles, with 21% showing increased risk of cardiovascular disease based on general population tools. Men receiving ...

Q. You recently wrote that testosterone does not increase the risk for heart attacks. But you overlooked the real risk of ...